- After quarantining a suspect product, the pharmacy, in collaboration with trading partners, conducts an investigation. The primary goal of this investigation is to:
Answer: determine if the product is illegitimate.
The entire purpose of quarantining and investigating a suspect product is to make a definitive determination: is the product authentic and safe, or is it illegitimate (e.g., counterfeit, diverted, stolen)? This determination dictates all subsequent actions, such as notifying the FDA and disposing of the product.
- What is the primary function of the unique serial number included in the DSCSA product identifier?
Answer: To allow for tracking of the product at the individual package level.
The serial number is a unique alphanumeric code assigned to each individual saleable unit. Its purpose is to enable the tracking and tracing of a specific package as it moves through the supply chain, which is a core component of the DSCSA's security framework.
- A pharmacy transfers a bottle of a prescription medication to another pharmacy to help with a temporary shortage. Under DSCSA, this transfer requires:
Answer: the creation and exchange of 3T documentation between the pharmacies.
When a pharmacy transfers a drug to another pharmacy for any reason other than fulfilling a specific patient prescription, it is a change of ownership that requires the passing of 3T documentation. While there is an exemption for specific patient needs, a transfer for general stock shortage is a distribution that falls under DSCSA rules.
- What is the purpose of the Transaction Statement (TS) that must be received with a prescription drug shipment?
Answer: It is an attestation by the seller that they are an authorized partner and have complied with DSCSA.
The Transaction Statement is a legal attestation. The entity transferring ownership of the product states that they are authorized, they received the product from an authorized partner, they received the 3T documentation, they did not knowingly ship a suspect or illegitimate product, and they have systems in place to comply with verification requirements.
- Which entity in the drug supply chain is defined by the DSCSA as a 'dispenser'?
Answer: A retail pharmacy.
Under the DSCSA, a 'dispenser' is a retail pharmacy, hospital pharmacy, or any other healthcare entity authorized by law to dispense or administer prescription drugs to patients. Wholesalers, manufacturers, and logistics providers are other types of trading partners with different roles and responsibilities.
- Under DSCSA, how can a pharmacy technician help verify that a drug wholesaler is an 'authorized trading partner'?
Answer: By ensuring the wholesaler is properly licensed with the state board of pharmacy.
An 'authorized trading partner' is one that is appropriately licensed or registered as required by federal and state law. For a wholesaler, this means holding a valid wholesale distribution license from the state board of pharmacy. Pharmacies must only conduct business with authorized partners.
- A key security feature of the DSCSA is its requirement for an 'interoperable, electronic' system. What does 'interoperable' mean in this context?
Answer: The system allows different trading partners' software to communicate and exchange data seamlessly.
'Interoperable' refers to the ability of different information systems, devices, and applications from various trading partners (manufacturers, wholesalers, pharmacies) to access, exchange, integrate, and cooperatively use data in a coordinated manner. This is essential for a seamless national track-and-trace system.
- What do the '3Ts' of drug tracing under the DSCSA represent?
Answer: Transaction Information, Transaction History, and Transaction Statement
The '3Ts' are the core components of the track-and-trace system. Transaction Information (TI) details the specific product in the transaction. Transaction History (TH) is a record of all prior transactions back to the manufacturer. Transaction Statement (TS) is an attestation from the seller confirming compliance.
- If a pharmacy receives a request from the FDA or an authorized trading partner for the transaction history of a specific drug, the pharmacy must provide this information:
Answer: within 2 business days.
DSCSA requires dispensers to be able to provide the relevant transaction information, history, and statement for a specific product upon request from the FDA or a trading partner. The response must be prompt, with the established expectation being within 2 business days.
- A pharmacy technician is stocking an order and notices the expiration date on a bottle of medication is different from the expiration date listed on the Transaction Information document. This discrepancy means the product should be handled as a:
Answer: suspect product.
Any inconsistency between the physical product and its transaction documentation is a red flag. A product with information that is inconsistent with its documentation is a reason to believe it may be suspect. The technician should quarantine the product and begin an investigation.
- What action is required if a pharmacy receives a product that has been the subject of a Class I recall and is also determined to be illegitimate under DSCSA?
Answer: The product must be quarantined and handled according to both recall and DSCSA procedures.
The product must be immediately quarantined. The pharmacy must then follow two parallel sets of procedures: the manufacturer's instructions for the recall AND the DSCSA requirements for illegitimate products, which includes notifying the FDA and trading partners. The two requirements are not mutually exclusive.
- The DSCSA's electronic, interoperable system for tracking drugs is designed to replace older, often paper-based systems known as:
Answer: pedigrees.
Prior to the DSCSA, some states required a 'pedigree,' which was a paper trail documenting the chain of custody for a drug. The DSCSA created a new, more robust, national standard that is electronic and traces products down to the individual package level, replacing the older pedigree requirements.
- For how long must a pharmacy maintain the transaction records (Transaction Information, History, and Statement) required by the DSCSA?
Answer: Six years
The DSCSA requires all trading partners, including dispensers like pharmacies, to retain all transaction documentation for a minimum of six years from the date of the transaction.
- If a pharmacy needs to verify the legitimacy of a specific product's unique identifier, the DSCSA allows them to make a verification request to the:
Answer: product's manufacturer.
The DSCSA establishes a verification system where a trading partner can query the manufacturer to confirm whether a product identifier (the combination of NDC, serial number, lot, and expiration date) corresponds to a legitimate product made by them. This is a key tool in investigating suspect products.
- The 2D data matrix barcode required by the DSCSA contains several key pieces of information. Which of the following is encoded in this barcode?
Answer: The product's unique serial number.
The 2D data matrix barcode is a machine-readable code that contains the four elements of the product identifier: the NDC, the unique serial number, the lot number, and the expiration date. This allows for rapid electronic capture of this essential tracking information.
- After quarantining the product, what is the pharmacy's next required action under DSCSA?
Answer: Notify the FDA and immediate trading partners.
Upon determining a product is illegitimate, the pharmacy must promptly notify the FDA by submitting Form FDA 3911. They must also notify their immediate trading partners (both who they bought it from and who they may have sold it to) to prevent the illegitimate product from moving further in the supply chain.
- What is the most appropriate first step for the technician to take according to DSCSA guidelines?
Answer: Quarantine the product and report it as 'suspect'.
A product with an altered, damaged, or unreadable label or product identifier is considered a 'suspect product' under DSCSA. The first and most critical step is to physically separate (quarantine) the product to prevent it from being dispensed or mixed with legitimate stock while an investigation is conducted.
- According to the DSCSA, which set of information constitutes a complete product identifier on a medication package?
Answer: NDC, serial number, lot number, and expiration date
The DSCSA mandates a unique product identifier on each package of a prescription drug. This identifier must include the standardized National Drug Code (NDC), a unique serial number, the lot number, and the product's expiration date in a machine-readable format.
- Which of the following products is generally EXEMPT from the serialization and tracing requirements of the DSCSA?
Answer: A container of sterile water for irrigation
DSCSA has several exemptions. Products like certain intravenous solutions (e.g., for fluid replacement, irrigation, or sterile water), medical gases, and homeopathic drugs are exempt from the track-and-trace requirements. Common prescription drugs like lisinopril, insulin, and antibiotics are covered.
- A patient returns an unopened, tamper-sealed box of medication for a refund. For the pharmacy to legally place this product back into its saleable inventory, the DSCSA requires that the pharmacy must be able to:
Answer: verify the product identifier and associate it with the original transaction documentation.
For a returned product to be placed back into stock for resale, the pharmacy must be able to verify the product using its unique identifier and associate it with the original transaction information, history, and statement to ensure its legitimacy and proper chain of custody.
